Immune thrombocytopenia (ITP) is commonly encountered in clinical practice. In 1996 the
American Society of Hematology published a landmark guidance paper designed to assist …

Background Bleeding is a complication of treatment with factor Xa inhibitors, but there are
no specific agents for the reversal of the effects of these drugs. Andexanet is designed to …

Background Many patients with the antiphospholipid antibody syndrome and recurrent
thrombosis receive doses of warfarin adjusted to achieve an international normalized ratio (INR) …

Background Warfarin is very effective in preventing recurrent venous thromboembolism but
is also associated with a substantial risk of bleeding. After three months of conventional …

Background: Rituximab, a monoclonal anti-CD20 antibody, is increasingly used to treat
idiopathic thrombocytopenic purpura (ITP). Purpose: To systematically review the literature on …

Background: Underutilization of anticoagulant prophylaxis may be due to lack of evidence
that prophylaxis prevents clinically important outcomes in hospitalized medical patients at risk …

ContextAntiphospholipid antibodies are autoantibodies directed against proteins that bind to
phospholipid. Antiphospholipid antibody syndrome (APS) refers to the association between …

Background: Dose adjustment or laboratory monitoring of low-molecular-weight heparin (LMWH)
is commonly recommended for patients with severe renal insufficiency (creatinine …

Background : Non–vitamin K oral anticoagulants (NOACs) do not require routine laboratory
monitoring. However, laboratory measurement may be desirable in special situations and …

The 4Ts is a pretest clinical scoring system for heparin-induced thrombocytopenia (HIT).
Although widely used in clinical practice, its predictive value for HIT in diverse settings and …